Cencora heads into the September stretch with a widening gap between analyst optimism and what the stock is actually doing — down nearly 3% on the week and 3.7% over the past month to $321.57, while a clutch of major banks sit on targets well above the current price.
The most striking tension this week is on the Street. The bullish case is well-populated. Wells Fargo raised its target sharply to $395 from $331 on August 11, maintaining Overweight. JP Morgan lifted to $390, UBS to $430 — both keeping Buy-equivalent ratings following the August 5 earnings beat, when the stock jumped 6.1% on the day. RBC initiated at Sector Perform with a $330 target on August 19, essentially a hold at current levels, and reiterated that stance on September 8 — a reminder that not everyone is chasing the upside. B of A holds a Neutral with a $285 target, the most cautious on the tape and the only one sitting below where the stock trades today. The overall consensus is "hold," with seven analysts split between outperform and hold ratings. Taken together, the Street is tilted bullish but far from unanimous, and the stock has given back most of the post-earnings pop without prompting any notable target cuts.
Valuation multiples tell a quietly softening story. The PE multiple has drifted lower over the past week to around 16.7x, and EV/EBITDA has eased to roughly 11.9x, down modestly over the past month. Those are not demanding levels for a healthcare distributor with a 5-year EBIT CAGR the company has historically supported. EPS momentum factor scores are middling — ranked in the 46th-52nd percentile range across 30 and 90-day windows — suggesting estimate revisions are neither accelerating nor deteriorating materially. The short score has been flat to slightly lower over the past ten sessions, sitting around 33.7, which places it in the lower half of the universe and signals no particular conviction from bears.
The lending market corroborates that low-conviction read. With short interest at just 2.4% of free float — down roughly 22% from a month ago — and availability at a vast 7,064%, there is no meaningful pressure in the borrow market. Cost to borrow has ticked up about 7% over the past week to 0.48%, but that is still an exceptionally low rate in absolute terms. Short interest did nudge up about 1.6% over the week, reversing a longer unwind, but the move is too small to read as a conviction shift. Options positioning is similarly relaxed — the put/call ratio at 0.41 is fractionally below its 20-day average of 0.42, essentially neutral and nowhere near the defensive extremes the 52-week high of 0.86 would represent.
One ownership note worth flagging: Walgreens Boots Alliance Holdings remains on the 13D activist register, having filed a SCHEDULE 13D/A as recently as June 2025. Its disclosed stake has slipped from 5.4% to 4.96% of shares outstanding. As per standard 13D/G disclosure rules, stakes at or below the 5% threshold may not trigger further filings even if the position is reduced further, so the current 9.6 million shares figure should be treated as "as last disclosed" rather than current. T. Rowe Price added a notable 1.75 million shares as of July 31, and JP Morgan Asset Management added 1.2 million shares as of September 1 — both are meaningful additions from two firms also sitting bullish through their analyst arms.
The next earnings event is November 4. Cencora's August 5 print produced a 6.1% single-day gain, its strongest recent reaction. Whether the stock can reclaim its post-earnings levels before then — or continues to drift toward the lower analyst targets — is the primary question the data leaves open.
See the live data behind this article on ORTEX.
Open COR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
